Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents

Author(s): Maricruz Anaya-Ruiz, Cindy Bandala, Gerardo Landeta, Patricia Martínez-Morales, Jose L. Zumaquero-Rios, Jorge Sarracent-Pérez, Martín Pérez-Santos*.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 14 , Issue 1 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Cancer is one of the leading causes of death in the world and it is necessary to develop new strategies for its treatment because most therapies have limited access to many types of tumors, as well as low therapeutic efficacy and high toxicity.

Objective: The present research aims to identify recent patents of drug delivery nanostructured systems that may have application in improving cancer treatment.

Methods: Recent patents regarding the drug delivery nanostructured systems for cancer treatment were obtained from the patent databases of the six main patent offices of the world: United States Patent and Trademark Office, European Patent Office, World Intellectual Property Organization, Japan Patent Office, State Intellectual Property Office of China and Korean Intellectual Property Office.

Results: A total of 1710 patent documents from 1998 to 2017 including "drug delivery nanostructured systems for cancer treatment" were retrieved. The top five countries in patent share were USA, China, South Korea, Canada and Germany. The universities and enterprises of USA had the highest amount of patents followed by institutions from China.

Conclusion: There is a strong tendency for the development of new nanostructured systems for the release of drugs; particularly, in recent years, the development of nanoparticles has focused on nanodiscs, gold nanoparticles and immunoliposomes.

Keywords: Cancer, delivering, drug, nanostructures, patent, therapy.

[1]
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[2]
Rivera-Guevara C, Camacho J. Tamoxifen and its new derivatives in cancer research. Recent Pat Anticancer Drug Discov 2011; 6(2): 237-45.
[3]
Tajiri K, Aonuma K, Sekine I. Cardiovascular toxic effects of targered cancer therapy. Jpn J Clin Oncol 2017; 47(9): 779-85.
[4]
Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targered therapies. Lancet 2016; 17(2): e529-41.
[5]
Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: A brief review. Adv Pharm Bull 2017; 7(3): 339-48.
[6]
Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget 2017; 8(35): 59950-64.
[7]
Sharbaf FG, Farhangi H, Assadi F. Prevention of chemotherapy-induced nephrotoxicity in children with cancer. Int J Prev Med 2017; 8: 76-82.
[8]
Matsos A, Loomes M, Zhou I, Macmillan E, Sabel I, Rotziokos E, et al. Chemotherapy-induced cognitive impairments: White matter pathologies. Cancer Treat Rev 2017; 61: 6-14.
[9]
Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen TL, Halsey C, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus. Lancet Oncol 2016; 17(6): e231-9.
[10]
El-Say KM, El-Sawy HS. Polymeric nanoparticles: Promising platform for drug delivery. Int J Pharmacol 2017; 528(1-2): 675-91.
[11]
Joanitti GA, Ganassin R, Rodrigues MC, Figueiro Longo JP, Jiang CS, Gu J, et al. Nanostructured systems for the organelle-specific delivery of anticancer drugs. Mini Rev Med Chem 2017; 17(3): 224-36.
[12]
Grinberg S, Linder C, Heldman E. Progress in lipid-based nanoparticles for cancer therapy. Crit Rev Oncog 2014; 19(3-4): 247-60.
[13]
Caraglia M, De Rosa G, Salzano G, Santini D, Lamberti M, Sperlongano P, et al. Nanotech revolution for the anti-cancer drug delivery through blood-brain barrier. Curr Cancer Drug Targets 2012; 12(3): 186-96.
[14]
Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: Is the enhanced permeability and retention effect sufficient for curing? Bioconjug Chem 2016; 27(10): 2225-38.
[15]
Patel S, Bhirde AA, Rusling JF, Chen X, Gutkind JS, Patel V. Nano delivers big: Designing molecular missiles for cancer therapeutics. Pharmaceutics 2011; 3(1): 34-52.
[16]
Sun W, Lu Y, Gu Z. Advances in anticancer protein delivery using micro-/nanoparticles. Part Part Syst Charact 2014; 31(12): 1204-22.
[17]
Chen J. Use of photoluminescent nanoparticles for photodynamic therapy. US2002127224 (2012)
[18]
Saltzman WM, Fahmy T, Fong P. Targeted and high density drug loaded polymeric materials. US7534449 (2009)
[19]
Liu J, Jiang Z, Zhang S, Saltzman WM. Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials 2009; 30(29): 5707-19.
[20]
Liu J, Jiang Z, Zhang S, Liu C. gross RA, Kyriakides TR, Saltzman WM. Biodegratation, biocompatibility, and drug delivery in poly(w.pentadecalactone-co-p-dioxanone) copolyesters. Biomaterials 2011; 32(27): 6646-54.
[21]
Sheder A, Shefer SD. pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients. US7670627 (2010)
[22]
Sengupta S, Zhao G, Capila I, Eavarone D, Sasisekharan R. Nanocell drug delivery system. US2007053845 (2007)
[23]
Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, et al. Temporal targeting of tumoour cells and neovasculature with a nanoscale delivery system. Nature 2005; 436(7050): 568-72.
[24]
Tomalia DA, Swanson DR, Huang B, et al. Dendritic polymers with enhanced amplification and interior functionality. US7985424 (2011)
[25]
Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 2007; 35(Pt1): 61-7.
[26]
Majoros IJ, Williams CR. Tomalia, Baker JR. New dendrimers; synthesis and characterization of POPAM-PAMAM hybrid dendrimers. Macromol 2008; 41(22): 8372-9.
[27]
Janaszewska A, Studzian M, Petersen JF, Ficker M, Paolucci V, Christensen JB, et al. Modified PAMAM dendrimer with 4-carbomethoxypyrrolidone surface groups.its uptake, effleux, and localization in a cell. Colloids Surf B Biointerfaces 2017; 159: 211-6.
[28]
Farokhzad OC, Jon SY, Langer RS. Targeted delivery of controlled release polymer systems. US7727969 (2010)
[29]
Farokhzad OC, Jon SY, Langer RS. Targeted delivery of controlled release polymer systems. US7550441 (2009)
[30]
Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan Dam Langer R. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 2004; 64(21): 7668-72.
[31]
Farokhzad OC, Cheng J, Teply BA, Sheriff I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006; 103(16): 6315-20.
[32]
Xiao Z, Levy-Nissenbaum E, Alexis F, Lupták A, Teply BA, Chan JM, et al. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano 2012; 6(1): 696-704.
[33]
Gao J, Ai H. Drug delivery system based on polymer nanoshells. US2005058603 (2005)
[34]
Li J, Li X, Ni X, Leong KW. Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from. US7297348 (2007)
[35]
Shastri V, Sussman E, Jayagopal A. Functionalized solid lipid nanoparticles and methods of making and using same. US2006083781 (2006)
[36]
Desimone JM, Rolland JP, Exner AE, et al. Nanoparticle fabrication methods, systems, and materials. WO2007024323 (2007)
[37]
Kurzrock R, Li L, Mehta K, Aggarawal BB. Liposomal curcumin for treatment of cancer. US7968115 (2011)
[38]
Au J, Wientjes MG. Tumor targeting drug-loaded particles. US8043631 (2011)
[39]
Hossainy SFA, Ludwing FN, Sridharan S. Nanoparticle releasing medical devices. US8043631 (2011)
[40]
Majoros IJ, Williams CR, Tomalia DA, Baker JR Jr. New dendrimers: Synthesis and characterization of POPAM-PAMAM hybrid dendrimers. Macromol 2008; 41(22): 8372-9.
[41]
Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009; 30(8): 1627-34.
[42]
Shuai X, Ai H, Nasongkla N, Kim S, Gao J. Micellar carriers based on block copolymers of poly (ε-caprolactone) and poly (ethylene glycol) for doxorubicin delivery. J Control Release 2004; 98(3): 415-26.
[43]
Li J, Li X, Ni X, Wang X, Li H, Leong KW. Self-assembled supramolecular hydrogels formed by biodegradable PEO-PHB-PEO triblock copolymers and α-cyclodextrin for controlled drug delivery. Biomaterials 2006; 27(22): 4132-40.
[44]
Jayagopal A, Sussman EM, Shastri VP. Functionalized solid lipid nanoparticles for transendothelial delivery. IEEE Trans Nanobiosci 2008; 7(1): 28-34.
[45]
Menaa F, Menaa B. Development of mitotane lipid nanocarriers and enantiomers: Two-in-one solution to efficiently treat adreno-cortical carcinoma. Curr Med Chem 2012; 19(34): 5854-62.
[46]
Gratton SE, Pohlhaus PD, Lee J, Guo J, Cho MJ, Desimone JM. Nanofabricated particles for engineered drug therapies: A preliminary biodistribution study of PRINT™ nanoparticles. J Control Release 2007; 121(1): 10-8.
[47]
Kurzrock R, Li L. Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. J Clin Oncol 2005; 23(16 suppl.): 4091-3.
[48]
Ryan RO. Lipophilic nucleic acid delivery vehicle and methods of use thereof. US8268796 (2012)
[49]
Ghosh M, Ren G, Simonsen JB, Ryan RO. Cationic lipid nanodisks as an siRNA delivery vehicle. Biochem Cell Biol 2014; 92(3): 200-5.
[50]
Crosby NM, Ghosh M, Su B, Beckstead JA, Kamei A, Simonsen JB, et al. Anti-CD20 single chain variable antibody fragment-apolipoprotein AI chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas. Biochem Cell Biol 2015; 93(4): 343-50.
[51]
Singh AT, Ghosh M, Forte TM, Ryan RO, Gordon LI. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk Lymphoma 2011; 52(8): 1537-43.
[52]
Ghosh M, Ryan RO. ApoE enhances nanodisk-mediated curcumin delivery to glioblastoma multiforme cells. Nanomedicine 2014; 9(6): 763-71.
[53]
Thaxton CS, Damiano MG, Zhang H, et al. Nanostructures for treating cancers and other conditions. US2015064255 (2015)
[54]
Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci USA 2013; 110(7): 2511-6.
[55]
Bell JB, Rink JS, Eckerdt F, Clymer J, Goldman S, Thaxton CS, et al. HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma. Sci Rep 2018; 8(1): 1211-7.
[56]
Schwendeman A, Cohen M, Subramanian C, et al. Compositions and methods for disease treatment using nanoparticle delivered compounds. US2017157149 (2017)
[57]
Kuai R, Subramanian C. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma. Int J Nanomed 2017; 12: 658-63.
[58]
Subramanian C, Kuai R, Zhu Q, White P, Moon JJ, Schwendeman A, et al. Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas. Surgery 2016; 159(1): 284-95.
[59]
Tamarkin L, Paciotti GF, Huhta MS. Nanotherapeutic colloidal metal compositions and methods. US2015018486 (2017)
[60]
Tamarkin L, Paciotti GF, Huhta MS. Nanotherapeutic colloidal metals. US2009104114 (2009)
[61]
Libutti SK, Paciotti GF, Byrnes AA, Alexander HR Jr, Gannon WE, Walker M, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010; 6(24): 6139-49.
[62]
Montclare JK, Frezzo J, Dai M, Chen R. Protein polymer gold nanoparticle hybrid materials for small molecule delivery. US2017196984 (2017)
[63]
Dai M, Frezzo JA, Sharma E, Chen R, Singh N, Yuvienco C, et al. Engineered protein polymer-gold nanoparticle hybrid materials for small molecule delivery. J Nanomed Nanotechnol 2016; 7(1)
[64]
Rotello VM, Mout R. Nanoparticle-protein complex for intracellular protein delivery. US20180228 (2018)
[65]
Mout R, Rotello VM. Cytosolic and nuclear delivery of crispr/cas9-ribonucleoprotein for gene editing using arginine functionalized gold nanoparticles. Bio Protoc 2017; 7(20): 12-9.
[66]
Mout R, Rotello VM. A general method for intracellular protein delivery through ‘E-tag’ protein engineering and arginine functionalized gold particles. Bio Protoc 2017; 7(24): e2661.
[67]
Wang B, Kiani MF, Tang Y. Compositions and methods for treatment of cancer. US2015366993. (2015)
[68]
Tang Y, Soroush F, Tong Z, Kiani MF, Wang B. Targeted multidrug delivery system to overcome chemoresistance in breast cancer. Int J Nanomedicine 2017; 12: 671-7.
[69]
Dumont N, Espelin C, Geretti E, et al. Treatment of HER2-intermediate cancer. WO2017136770 (2017)
[70]
Espelin CW, Leonard SC, Geratti E, Wickham TJ, Hendriks BS. Dual HER2 targeting with trastuzumab and liposomal-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer. Cancer Res 2016; 76(6): 1517-27.
[71]
Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, et al. HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracucline.naive, HER2-positive, locally advanced/metastatic breast cancer. MBC Cancer 2016; 16: 352-8.
[72]
Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol 2012; 262(1): 1-10.
[73]
Chang EH, Kim S, Rait A. Targeted liposomes. US2014120157 (2014)
[74]
Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett 2015; 369(1): 250-8.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 14
ISSUE: 1
Year: 2019
Page: [85 - 94]
Pages: 10
DOI: 10.2174/1574892813666181031154146
Price: $58

Article Metrics

PDF: 57
HTML: 1